Clinical trials: Diabetes, Type 1
Type 1 Diabetes
Qingdao: Insulin Pump Follow-Up Program
The purpose of the study is to observe/ collect clinical data, subject users' feedback, and device data to better understand the real-life usage and acceptance of the 722 Pump in type 1 diabetes subjects,<18 years of age, and the…
- Trial name
- NCT02655666
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Insulin-Dependent
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Type 1
- Trial name
- NCT01973920
- Testing
- Oshadi Icp
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Oshadi Drug Administration
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Diabetes Mellitus, Type 2
Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions
ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can…
- Trial name
- ECLIPSE (NCT05354297)
- Testing
- Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LifeScan
Type 1 Diabetes
ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash…
- Trial name
- ADAPT (NCT04235504)
- Testing
- MDI, AHCL
- Where
- 14 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
- Trial name
- CREATE-1 (NCT05626712)
- Testing
- CELZ-201 Administration, Control Group
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Creative Medical Technology Holdings Inc
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both…
- Trial name
- BOOST™ (NCT01045707)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 92 sites in United States, Austria and 7 more
- Volunteers
- 530 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir compared to NPH insulin…
- Trial name
- NCT00184665
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 29 sites in Argentina, Australia and 8 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the trial drug in the body), and Safety of…
- Trial name
- NCT02938572
- Testing
- NNC0143-0406, Insulin Aspart
- Where
- Austria
- Volunteers
- 47 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104…
- Trial name
- NCT00226330
- Testing
- Tesaglitazar, Pioglitazone
- Where
- 171 sites in United States, Argentina and 5 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients With Diabetes Using Levemir® FlexPen®
This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00670683
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 797 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Thailand.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00805922)
- Testing
- No treatment given
- Where
- Thailand
- Volunteers
- 2,342 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease
- Trial name
- iINHALE 8 (NCT00472953)
- Testing
- inhaled human insulin, insulin aspart
- Where
- 27 sites in Argentina, India and 5 more
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus
- Trial name
- NCT01222078
- Testing
- otelixizumab
- Where
- 2 sites in France, Germany
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Patients
Drug Interaction Study Between Dorzagliatin and Empagliflozin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM.
- Trial name
- NCT03790787
- Testing
- Empagliflozin, Dorzagliatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hua Medicine Limited
Type 1 Diabetes Mellitus
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT02044848
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 2
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts A and C).
- Trial name
- NCT04305587
- Testing
- PF-07081532, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo
This study is the follow-up of study IMCY-T1D 001 (EudraCT: 2016-003514-27, NCT03272269) in which patients with recent onset T1D have been treated with IMCY-0098 or placebo.
- Trial name
- IMCY-T1D-002 (NCT04190693)
- Where
- 19 sites in Belgium, Denmark and 5 more
- Volunteers
- 30 people
- Sponsor
- Imcyse SA
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.